Precision Symptom Phenotyping Identifies Early Clinical and Proteomic Predictors of Distinct COVID-19 Sequelae - Report - MDSpire

Precision Symptom Phenotyping Identifies Early Clinical and Proteomic Predictors of Distinct COVID-19 Sequelae

  • By

  • Nusrat J Epsi

  • Josh G Chenoweth

  • Paul W Blair

  • David A Lindholm

  • Anuradha Ganesan

  • Tahaniyat Lalani

  • Alfred Smith

  • Rupal M Mody

  • Milissa U Jones

  • Rhonda E Colombo

  • Christopher J Colombo

  • Christina Schofield

  • Evan C Ewers

  • Derek T Larson

  • Catherine M Berjohn

  • Ryan C Maves

  • Anthony C Fries

  • David Chang

  • Andrew Wyatt

  • Ann I Scher

  • Celia Byrne

  • Jennifer Rusiecki

  • David L Saunders

  • Jeffrey Livezey

  • Allison Malloy

  • Samantha Bazan

  • Carlos Maldonado

  • Margaret Sanchez Edwards

  • Katrin Mende

  • Mark P Simons

  • Robert J O’Connell

  • David R Tribble

  • Brian K Agan

  • Timothy H Burgess

  • Simon D Pollett

  • Stephanie A Richard

  • June 25, 2024

  • 0 min

Share

Targeted Symptom Profiling Identifies Distinct Post-COVID Condition Phenotypes

Overview

This study analyzed 1988 SARS-CoV-2 positive individuals to identify distinct post-COVID condition (PCC) phenotypes using machine learning. Three symptom clusters—sensory, fatigue/cognitive, and respiratory—were identified, each associated with specific clinical risk factors and early inflammatory markers.

Background

Post-COVID conditions (PCC), or long COVID, encompass a wide range of persistent symptoms following SARS-CoV-2 infection, complicating diagnosis and treatment. Existing broad definitions hinder precise characterization and prognostication. Understanding symptom patterns and their biological underpinnings is critical to improving clinical management and trial design for PCC.

Data Highlights

Symptom ClusterKey SymptomsClinical AssociationsEarly Inflammatory Markers
SensoryLoss of smell and/or tasteAll outpatients during acute infectionElevated ICAM-1
Fatigue/Difficulty ThinkingFatigue, cognitive difficultiesLinked to elevated D-dimer and IL-1RA post-infectionElevated D-dimer, IL-1RA
Difficulty Breathing/Exercise IntoleranceDyspnea, exercise intoleranceHigher obesity prevalence and COVID-19 hospitalization ratesNot specified

Key Findings

  • Three distinct PCC symptom clusters were identified: sensory, fatigue/cognitive, and respiratory.
  • The sensory cluster was exclusively observed in patients managed as outpatients during acute COVID-19.
  • The respiratory cluster was associated with higher obesity rates and increased likelihood of hospitalization.
  • Early post-infection elevations in D-dimer and IL-1RA predicted fatigue/cognitive symptoms.
  • Elevated ICAM-1 concentrations early post-infection were linked to sensory symptoms.
  • Machine learning approaches enabled refined phenotyping of PCC beyond broad symptom definitions.

Clinical Implications

Recognizing distinct PCC phenotypes allows clinicians to better predict long-term outcomes based on early symptom profiles and inflammatory markers. This stratification may guide personalized monitoring and targeted interventions. Furthermore, these findings support the development of more precise diagnostic criteria and tailored clinical trials for PCC therapies.

Conclusion

This study demonstrates that data-driven symptom profiling coupled with inflammatory biomarker analysis can delineate meaningful PCC phenotypes, enhancing understanding and management of post-COVID conditions. Further validation could improve diagnosis, prognostication, and treatment strategies.

References

  1. Original Study -- Targeted Symptom Profiling Reveals Early Clinical and Proteomic Indicators of Varied Post-COVID Conditions

Original Source(s)

Precision Symptom Phenotyping Identifies Early Clinical and Proteomic Predictors of Distinct COVID-19 Sequelae

  • by Nusrat J Epsi, Josh G Chenoweth, Paul W Blair, David A Lindholm, Anuradha Ganesan, Tahaniyat Lalani, Alfred Smith, Rupal M Mody, Milissa U Jones, Rhonda E Colombo, Christopher J Colombo, Christina Schofield, Evan C Ewers, Derek T Larson, Catherine M Berjohn, Ryan C Maves, Anthony C Fries, David Chang, Andrew Wyatt, Ann I Scher, Celia Byrne, Jennifer Rusiecki, David L Saunders, Jeffrey Livezey, Allison Malloy, Samantha Bazan, Carlos Maldonado, Margaret Sanchez Edwards, Katrin Mende, Mark P Simons, Robert J O’Connell, David R Tribble, Brian K Agan, Timothy H Burgess, Simon D Pollett, Stephanie A Richard

  • June 25, 2024

Related Content

Antibiotics May Not Help Mild COVID

A retrospective cohort study of more than 520,000 hospitalized patients found no clinically meaningful improvement in deterioration or mortality with early treatment targeting community-acquired pneumonia.

Hantavirus Outbreak Revives COVID-Era False Health Claims — The Monitor

Increased anti-nucleocapsid secretory IgA and consumption of complement component 3 in post-COVID syndrome patients